NATCO Pharma Crecimiento futuro

Future controles de criterios 0/6

Se prevé que los ingresos y los beneficios de NATCO Pharma disminuyan a un ritmo anual de 5.1% y 20.4% respectivamente. Se espera que el BPA disminuya en un 19.5% al año. Se prevé que la rentabilidad financiera sea de 17.8% en 3 años.

Información clave

-20.4%

Tasa de crecimiento de los beneficios

-19.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	17.8%
Tasa de crecimiento de los ingresos	-5.1%
Rentabilidad financiera futura	17.8%
Cobertura de analistas	Good
Última actualización	20 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Nov 15

Recent updates

NATCO Pharma (NSE:NATCOPHARM) Has Announced A Dividend Of ₹1.50

Nov 18

Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Nov 15

We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease

Oct 13

NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market

Aug 13

If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity

Jul 15

NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly

Jun 30

NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors

Jun 14

NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

May 30

NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

Feb 18

NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Feb 17

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jan 25

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued

Jan 09

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Dec 13

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued

Sep 30

Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

Sep 12

NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Aug 12

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

Jul 16

NATCO Pharma Limited (NSE:NATCOPHARM) Shares Could Be 44% Below Their Intrinsic Value Estimate

Apr 20

Is NATCO Pharma Limited (NSE:NATCOPHARM) Trading At A 46% Discount?

Dec 20

NATCO Pharma's (NSE:NATCOPHARM) Upcoming Dividend Will Be Larger Than Last Year's

Aug 12

Does NATCO Pharma (NSE:NATCOPHARM) Have A Healthy Balance Sheet?

Jun 23

Broker Revenue Forecasts For NATCO Pharma Limited (NSE:NATCOPHARM) Are Surging Higher

Jun 02

Previsiones de crecimiento de beneficios e ingresos

NSEI:NATCOPHARM - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2027	37,151	8,965	12,188	15,176	8
3/31/2026	55,674	21,668	17,718	18,732	10
3/31/2025	50,546	21,570	15,571	16,763	9
9/30/2024	45,638	19,448	12,838	17,163	N/A
6/30/2024	43,490	16,365	N/A	N/A	N/A
3/31/2024	40,020	13,883	8,529	12,116	N/A
12/31/2023	38,298	12,778	N/A	N/A	N/A
9/30/2023	35,637	11,274	5,230	7,477	N/A
6/30/2023	29,630	8,152	N/A	N/A	N/A
3/31/2023	27,085	7,153	6,435	8,491	N/A
12/31/2022	24,074	3,890	N/A	N/A	N/A
9/30/2022	24,754	4,071	5,575	8,302	N/A
6/30/2022	24,191	4,154	N/A	N/A	N/A
3/31/2022	19,462	1,700	-1,962	465	N/A
12/31/2021	16,833	2,735	N/A	N/A	N/A
9/30/2021	14,780	2,558	-2,457	230	N/A
6/30/2021	18,990	3,931	N/A	N/A	N/A
3/31/2021	20,561	4,409	465	2,988	N/A
12/31/2020	21,756	4,820	N/A	N/A	N/A
9/30/2020	23,026	5,238	1,554	4,466	N/A
6/30/2020	19,861	4,404	N/A	N/A	N/A
3/31/2020	19,150	4,608	587	4,173	N/A
12/31/2019	19,159	4,875	N/A	N/A	N/A
9/30/2019	19,904	5,425	-2,200	1,600	N/A
6/30/2019	20,482	6,060	N/A	N/A	N/A
3/31/2019	20,945	6,444	2,071	6,688	N/A
12/31/2018	24,066	8,235	N/A	N/A	N/A
9/30/2018	24,121	8,815	N/A	N/A	N/A
6/30/2018	22,953	7,838	N/A	N/A	N/A
3/31/2018	21,848	6,962	N/A	4,636	N/A
12/31/2017	19,817	5,730	N/A	N/A	N/A
9/30/2017	20,895	5,506	N/A	4,985	N/A
6/30/2017	21,679	5,323	N/A	N/A	N/A
3/31/2017	20,202	4,860	N/A	3,458	N/A
12/31/2016	17,697	3,680	N/A	N/A	N/A
9/30/2016	13,692	2,113	N/A	N/A	N/A
6/30/2016	12,431	1,748	N/A	N/A	N/A
3/31/2016	10,423	1,549	N/A	1,122	N/A
12/31/2015	9,355	1,494	N/A	N/A	N/A
9/30/2015	8,549	1,266	N/A	N/A	N/A
6/30/2015	8,390	1,294	N/A	N/A	N/A
3/31/2015	7,305	1,293	N/A	927	N/A
12/31/2014	8,089	1,042	N/A	N/A	N/A
9/30/2014	8,108	1,199	N/A	N/A	N/A
6/30/2014	7,648	1,144	N/A	N/A	N/A
3/31/2014	7,389	1,027	N/A	1,440	N/A
12/31/2013	7,078	900	N/A	N/A	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que los beneficios de NATCOPHARM disminuyan en los próximos 3 años (-20.4% al año).

Beneficios vs. Mercado: Se prevé que los beneficios de NATCOPHARM disminuyan en los próximos 3 años (-20.4% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de NATCOPHARM disminuyan en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos de NATCOPHARM disminuyan en los próximos 3 años (-5.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos de NATCOPHARM disminuyan en los próximos 3 años (-5.1% al año).

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de NATCOPHARM sea baja dentro de 3 años (17.8%).

NATCO Pharma Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Consensus EPS estimates increase by 11%

Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Consensus EPS estimates increase by 14%

Price target increased by 11% to ₹1,180

Consensus EPS estimates increase by 14%

Price target increased by 9.1% to ₹1,064

Recent updates

Consensus EPS estimates increase by 11%

NATCO Pharma (NSE:NATCOPHARM) Has Announced A Dividend Of ₹1.50

Earnings Beat: NATCO Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Dividend of ₹1.50 announced

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

NATCO Pharma Limited to Report First Half, 2025 Results on Nov 12, 2024

We Ran A Stock Scan For Earnings Growth And NATCO Pharma (NSE:NATCOPHARM) Passed With Ease

Insider recently sold ₹30m worth of stock

High number of new directors

Natco Pharma Limited Submits Abbreviated New Drug Application Containing A Paragraph IV Certification with the U.S. Food and Drug Administration

Less than half of directors are independent

New minor risk - Insider selling

Consensus EPS estimates increase by 14%

Price target increased by 11% to ₹1,180

NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2024-25, Payable from August 30, 2024

Dividend of ₹3.00 announced

First quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

NATCO Pharma Limited's (NSE:NATCOPHARM) Shares Bounce 26% But Its Business Still Trails The Market

NATCO Pharma Limited Announces Term Completion of Directors

NATCO Pharma Limited, Annual General Meeting, Sep 30, 2024

NATCO Pharma Limited Announces Resignation of Sanivarapu Ravi Prakash Reddy as Senior Vice President - Operations

NATCO Pharma Limited to Report Q1, 2025 Results on Aug 12, 2024

If EPS Growth Is Important To You, NATCO Pharma (NSE:NATCOPHARM) Presents An Opportunity

NATCO Pharma (NSE:NATCOPHARM) Seems To Use Debt Rather Sparingly

Board Member recently sold ₹6.0m worth of stock

NATCO Pharma Limited's (NSE:NATCOPHARM) Earnings Are Not Doing Enough For Some Investors

Investor sentiment improves as stock rises 21%

Consensus EPS estimates increase by 14%

Price target increased by 9.1% to ₹1,064

NATCO Pharma Limited (NSE:NATCOPHARM) Exceeded Expectations And The Analyst Consensus Has Been Reviewing Its Models

New major risk - Revenue and earnings growth

Full year 2024 earnings: EPS and revenues exceed analyst expectations

NATCO Pharma Limited to Report Q4, 2024 Results on May 27, 2024

Calculating The Fair Value Of NATCO Pharma Limited (NSE:NATCOPHARM)

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Now 22% undervalued

Now 20% undervalued

Consensus EPS estimates increase by 17%

Investor sentiment improves as stock rises 16%

NATCO Pharma (NSE:NATCOPHARM) Is Due To Pay A Dividend Of ₹1.25

Upcoming dividend of ₹1.25 per share

NATCO Pharma Limited Just Beat EPS By 223%: Here's What Analysts Think Will Happen Next

NATCO Pharma Limited (NSE:NATCOPHARM) Surges 25% Yet Its Low P/E Is No Reason For Excitement

Price target increased by 8.9% to ₹895

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Corporate Action-Board Approves Third Interim Dividend for the Financial Year 2023-24, Payable on 4 March 2024

NATCO Pharma Limited to Report Q3, 2024 Results on Feb 14, 2024

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 37% Undervalued

Board Member recently sold ₹8.0m worth of stock

Insider recently sold ₹1.2m worth of stock

Board Member recently sold ₹7.9m worth of stock

Does NATCO Pharma (NSE:NATCOPHARM) Deserve A Spot On Your Watchlist?

Insider recently sold ₹1.6m worth of stock

NATCO Pharma Limited Declares Second Interim Dividend for the Financial Year 2023-24, Payable on 1 December, 2023

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

NATCO Pharma Limited to Report Q2, 2024 Results on Nov 14, 2023

An Intrinsic Calculation For NATCO Pharma Limited (NSE:NATCOPHARM) Suggests It's 42% Undervalued

Here's Why We Think NATCO Pharma (NSE:NATCOPHARM) Might Deserve Your Attention Today

NATCO Pharma Limited, Annual General Meeting, Sep 29, 2023

Upcoming dividend of ₹7.00 per share at 0.7% yield

NATCO Pharma (NSE:NATCOPHARM) Is Paying Out A Larger Dividend Than Last Year

Price target increased by 9.6% to ₹734

NATCO Pharma Limited Declares Interim Dividend for the Financial Year 2023-24

First quarter 2024 earnings: EPS exceeds analyst expectations

NATCO Pharma Limited to Report Q1, 2024 Results on Aug 09, 2023

Is NATCO Pharma (NSE:NATCOPHARM) A Risky Investment?

NATCO Pharma Limited (NSEI:NATCOPHARM) agreed to acquire Zista Pharma Limited for $3 million.

Full year 2023 earnings: Revenues and EPS in line with analyst expectations